KemPharm Inc (NASDAQ:KMPH) shares hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $1.15 and last traded at $1.16, with a volume of 5600 shares changing hands. The stock had previously closed at $1.20.

A number of brokerages recently issued reports on KMPH. ValuEngine downgraded KemPharm from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. Zacks Investment Research downgraded KemPharm from a “hold” rating to a “sell” rating in a report on Tuesday, January 15th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $10.75.

The firm has a market capitalization of $32.54 million, a price-to-earnings ratio of -0.50 and a beta of 1.63.

KemPharm (NASDAQ:KMPH) last posted its earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($0.46) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.46). As a group, research analysts expect that KemPharm Inc will post -1.37 earnings per share for the current year.

Hedge funds have recently bought and sold shares of the business. Janney Montgomery Scott LLC purchased a new position in shares of KemPharm during the 4th quarter worth approximately $44,000. Change Path LLC purchased a new position in shares of KemPharm during the 4th quarter worth approximately $67,000. Wedbush Securities Inc. purchased a new position in shares of KemPharm during the 1st quarter worth approximately $72,000. Northern Trust Corp grew its holdings in shares of KemPharm by 34.0% during the 4th quarter. Northern Trust Corp now owns 43,445 shares of the specialty pharmaceutical company’s stock worth $78,000 after acquiring an additional 11,014 shares during the period. Finally, BlackRock Inc. grew its holdings in shares of KemPharm by 25.0% during the 4th quarter. BlackRock Inc. now owns 90,426 shares of the specialty pharmaceutical company’s stock worth $161,000 after acquiring an additional 18,079 shares during the period. Hedge funds and other institutional investors own 34.30% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2019/05/15/kempharm-kmph-reaches-new-1-year-low-at-1-15.html.

KemPharm Company Profile (NASDAQ:KMPH)

KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder.

Featured Story: S&P 500 Index

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.